Empagliflozin/Metformin

DRUG5 trials

Sponsors

Boehringer Ingelheim, University Medical Centre Ljubljana, JW Pharmaceutical

Conditions

Diabetes ComplicationsDiabetes Mellitus, Type 1HealthyHypoglycemic AgentsType 2 Diabetes Mellitus (T2DM)Vascular Stiffness

Phase 1

Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together

CompletedNCT01811953

Boehringer IngelheimHealthy

Start: 2013-03-31End: 2013-05-31Updated: 2015-07-27

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects

CompletedNCT02230995

Boehringer IngelheimHealthy

Start: 2014-09-30End: 2014-10-31Updated: 2017-03-09

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female

CompletedNCT02266472

Boehringer IngelheimHealthy

Start: 2014-11-30End: 2014-12-31Updated: 2017-03-09

Phase 4

The Effects of Empagliflozin on Arterial Wall Characteristics

University Medical Centre LjubljanaDiabetes Complications, Diabetes Mellitus, Type 1, Hypoglycemic Agents +1

Start: 2018-03-01End: 2019-01-30Target: 120Updated: 2018-08-21

Glycemic Variability of Combination Therapies in T2DM

RecruitingNCT07442006

JW PharmaceuticalType 2 Diabetes Mellitus (T2DM)

Start: 2025-10-29End: 2027-03-31Target: 178Updated: 2026-03-02

Related Papers

Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus

Cardiovascular Diabetology2018-12-0192 citations